Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Cash & Equivalents (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Cash & Equivalents for 8 consecutive years, with $110.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 29.02% to $110.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $110.8 million through Dec 2025, up 29.02% year-over-year, with the annual reading at $110.8 million for FY2025, 29.02% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $110.8 million at Precision Biosciences, up from $44.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $212.1 million in Q3 2022, with the low at $44.9 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $132.5 million, with a median of $130.7 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents soared 59.98% in 2021, then plummeted 54.56% in 2025.
  • Over 5 years, Cash & Equivalents stood at $143.7 million in 2021, then soared by 31.96% to $189.6 million in 2022, then tumbled by 38.45% to $116.7 million in 2023, then dropped by 26.38% to $85.9 million in 2024, then rose by 29.02% to $110.8 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $110.8 million, $44.9 million, and $62.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.